Surrey Heartlands

Joint Formulary & PAD

Apremilast - Psoriatic arthritis

You are here : Home > Formulary Search > Apremilast - Psoriatic arthritis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
ICB
NICE
Restrictions / Comments :

Documentation

Guidelines (Local)
Psoriatic Arthritis High cost immunomodulator drug pathway Apr-24.pdf
Policy Statement
Apremilast for PsA - Policy statement APC 265-2017 May17.pdf
NICE Technology Appraisal
NICE TA433 - Apremilast for treating active psoriatic arthritis
Evidence Review
Apremilast for treating active psoriatic arthritis - NICE briefing paper - May 2017

PAD Profile

ChemicalSubstance :
Apremilast
Indication :
Psoriatic arthritis
Group Name :
Keywords :
Biologic, NICE, immunosuppressant, phosphodiesterase type-4 inhibitor, PDE4 inhibitor, DMARD, bDmard, Disease modulating, Reumatology, biosimilar
Brand Names Include :
Otezla
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
4

Other Indications

Below are listed other indications that Apremilast is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Psoriatic arthritis.

Committee Recommendations (3)

03 Apr 24 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated  Psoriatic arthritis high cost immunomodulator treatment pathway.

02 Dec 20 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands ICS Area Prescribing Committee have agreed an update of the Psoriatic Arthritis High Cost immunomodulator Drug Treatment Pathway. 

The pathway has been updated following guidance from the Regional Medicines Optimisation Committee in May 2020, in relation to the sequential use of biologic medicines. 

03 May 17 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends Apremilast as a treatment option for treating active psoriatic arthritis in line with NICE TA433 (22nd February 2017).

Apremilast is a payment by results excluded drug which will be considered RED on the traffic light system.

Please see the current psoriatic arthritis treatment pathway below.